HomeCompareIOBCF vs GBDC

IOBCF vs GBDC: Dividend Comparison 2026

IOBCF yields 1.84% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IOBCF wins by $24.50M in total portfolio value· pulled ahead in Year 10
10 years
IOBCF
IOBCF
● Live price
1.84%
Share price
$15.00
Annual div
$0.28
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.35M
Annual income
$41,068,608.41
Full IOBCF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — IOBCF vs GBDC

📍 IOBCF pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIOBCFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IOBCF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IOBCF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IOBCF
Annual income on $10K today (after 15% tax)
$156.68/yr
After 10yr DRIP, annual income (after tax)
$34,908,317.15/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, IOBCF beats the other by $20,925,193.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IOBCF + GBDC for your $10,000?

IOBCF: 50%GBDC: 50%
100% GBDC50/50100% IOBCF
Portfolio after 10yr
$33.10M
Annual income
$28,759,671.13/yr
Blended yield
86.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

IOBCF
No analyst data
Altman Z
2.4
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IOBCF buys
0
GBDC buys
0
No recent congressional trades found for IOBCF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIOBCFGBDC
Forward yield1.84%11.86%
Annual dividend / share$0.28$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%51.1%
Portfolio after 10y$45.35M$20.85M
Annual income after 10y$41,068,608.41$16,450,733.83
Total dividends collected$44.99M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: IOBCF vs GBDC ($10,000, DRIP)

YearIOBCF PortfolioIOBCF Income/yrGBDC PortfolioGBDC Income/yrGap
1$11,069$368.67$12,492$1,791.70$1.4KGBDC
2$12,606$762.74$16,527$3,160.58$3.9KGBDC
3$15,112$1,623.72$23,588$5,904.90$8.5KGBDC
4$19,809$3,638.35$37,141$11,901.65$17.3KGBDC
5$30,109$8,913.99$66,205$26,463.38$36.1KGBDC
6$57,543$25,325.84$137,452$66,612.65$79.9KGBDC
7$152,040$90,469.27$342,372$195,298.53$190.3KGBDC
8$609,485$446,801.92$1,053,292$686,954.33$443.8KGBDC
9$4,000,001$3,347,852.94$4,111,439$2,984,416.95$111.4KGBDC
10← crossover$45,348,610$41,068,608.41$20,849,974$16,450,733.83+$24.50MIOBCF

IOBCF vs GBDC: Complete Analysis 2026

IOBCFStock

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Full IOBCF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this IOBCF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IOBCF vs SCHDIOBCF vs JEPIIOBCF vs OIOBCF vs KOIOBCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.